Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-α or imatinib

被引:0
作者
Kiani, A
Habermann, I
Schakel, K
Neubauer, A
Rogge, L
Ehninger, G
机构
[1] Tech Univ Dresden, Med Klin & Poliklin 1, D-01307 Dresden, Germany
[2] Tech Univ Dresden, Dept Med, D-01307 Dresden, Germany
[3] Tech Univ Dresden, Inst Immunol, D-01307 Dresden, Germany
[4] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, D-01307 Dresden, Germany
[5] Univ Marburg, Univ Hosp, Dept Hematol Oncol & Immunol, Marburg, Germany
[6] Inst Pasteur, Dept Immunol, F-75724 Paris, France
关键词
chronic myeloid leukemia; T-helper cells; Th1; Th2; IL-10;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives. CD4(+) T helper cells are an integral part of effective immune responses against various malignancies; however in tumor-bearing patients they are frequently functionally unresponsive. T helper cells of patients with chronic myeloid leukemia (CML), analyzed as part of mononuclear cell fractions, show a loss of signaling molecules, a compromised Th1 cytokine production and a shift towards a non-productive Th2 state. The underlying mechanism is unknown and may involve intrinsic T cell defects as well as indirect effects mediated by leukemia or antigen-presenting cells. The purpose of the present study was to analyze the intrinsic cytokine-producing capacity of purified CIVIL T helper cells in the absence of other cell types. Design and Methods. Untouched CD4(+) T cells with a purity of more than 90% were isolated from 10 patients with Ph+ chronic phase CML on maintenance treatment with hydroxyurea. The cells were isolated by density gradient centrifugation followed by immunomagnetic depletion of leukemia and accessory cells. The ex vivo cytokine-producing capacity of CML T helper cells in response to polyclonal stimulation with anti-CD3 and anti-CD28 was then compared to that of cells purified from matched healthy volunteers. Results. T helper cells purified from CML patients produced comparable amounts of the Th1 cytokines interleukin (IL)-2 and interferon (IFN)-gamma as tells purified from healthy volunteers. Likewise, no difference between CML and control T helper cells was found with respect to the Th2 cytokines, IL-4 and IL-13, as well as the immunomodulatory cytokine, IL-10. Interpretation and Conclusions. In the absence of leukemia and accessory cells, the intrinsic cytokine-producing capacity of CML T helper cells is normal. A Th2 shift was not detected, and the predominant presence of an IL-10-producing, immunosuppressive T helper cell subset could be excluded.
引用
收藏
页码:754 / 761
页数:8
相关论文
共 32 条
  • [21] BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors
    Pawelec, G
    Max, H
    Halder, T
    Bruserud, O
    Merl, A
    daSilva, P
    Kalbacher, H
    [J]. BLOOD, 1996, 88 (06) : 2118 - 2124
  • [22] Posthuma EFM, 1999, BLOOD, V93, P3863
  • [23] Reuben JM, 2000, CLIN CANCER RES, V6, P1671
  • [24] Drug therapy: Imatinib mesylate - A new oral targeted therapy.
    Savage, DG
    Antman, KH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) : 683 - 693
  • [25] Chronic myeloid leukemia
    Sawyers, CL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (17) : 1330 - 1340
  • [26] Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias
    Schmidt, M
    Nagel, S
    Proba, J
    Thiede, C
    Ritter, M
    Waring, JF
    Rosenbauer, F
    Huhn, D
    Wittig, B
    Horak, I
    Neubauer, A
    [J]. BLOOD, 1998, 91 (01) : 22 - 29
  • [27] HEMATOLOGIC REMISSION AND CYTOGENETIC IMPROVEMENT INDUCED BY RECOMBINANT HUMAN INTERFERON-ALPHA-A IN CHRONIC MYELOGENOUS LEUKEMIA
    TALPAZ, M
    KANTARJIAN, HM
    MCCREDIE, K
    TRUJILLO, JM
    KEATING, MJ
    GUTTERMAN, JU
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (17) : 1065 - 1069
  • [28] A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Iib2a2 construct
    ten Bosch, GJA
    Kessler, JH
    Joosten, AM
    Bres-Vloemans, AA
    Geluk, A
    Godthelp, BC
    van Bergen, J
    Melief, CJM
    Leeksma, OC
    [J]. BLOOD, 1999, 94 (03) : 1038 - 1045
  • [29] CD4 T cells and their role in antitumor immune responses
    Toes, REM
    Ossendorp, F
    Offringa, R
    Melief, CJM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (05) : 753 - 756
  • [30] Type I and type II T cell profiles in chronic myelogenous leukemia
    Tsuda, H
    Yamasaki, H
    [J]. ACTA HAEMATOLOGICA, 2000, 103 (02) : 96 - 101